SEC Form 4 · accession 0001179022-18-000056
GALECTIN THERAPEUTICS INC · GALT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jack W Callicutt
Officer — Chief Financial Officer
Period of report
Jun 19, 2018
Accepted (ET)
Jun 21, 2018 · 4:18 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001133416
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jun 19, 2018 | M | 102,733 | $4.41 | A | 103,993 | D | |
| Common Stock | Jun 19, 2018 | M | 26,000 | $3.45 | A | 129,993 | D | |
| Common StockF3 | Jun 19, 2018 | S | 128,733 | $9.0108 | D | 1,260 | D | |
| Common Stock | Jun 20, 2018 | M | 97,267 | $4.41 | A | 98,527 | D | |
| Common StockF4 | Jun 20, 2018 | S | 97,267 | $8.0812 | D | 1,260 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock option (right to buy)F1 | $4.41 | Jun 19, 2018 | M | 102,733 | D | — | Jul 1, 2023 | Common Stock | 102,733 | 97,267 | D |
| Stock option (right to buy)F2 | $3.45 | Jun 19, 2018 | M | 26,000 | D | — | Jan 29, 2025 | Common Stock | 26,000 | 0 | D |
| Stock option (right to buy)F1 | $4.41 | Jun 20, 2018 | M | 97,267 | D | — | Jul 1, 2023 | Common Stock | 97,267 | 0 | D |
Explanation of responses
- F1The options vested as follows: (i) 12.5% on December 31, 2013, (ii) 25% on December 31, 2014, (iii) 25% on December 31, 2015, and (iv) 50% on December 31, 2016.
- F2The options vested as follows: 25% on January 29, 2016, the grant date, with the remainder vesting ratably on a monthly basis over a three year period.
- F3The shares were sold in multiple transactions at prices ranging from $9.00 to $9.0266. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
- F4The shares were sold in multiple transactions at prices ranging from $8.0054 to $8.2592. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.